Johnson & Johnson Depression

US FDA approves new nasal spray for depression treatment

FDA approves Johnson & Johnson’s ketamine-derived nasal spray for depression as stand-alone treatment

The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult population.

Fox Business · 2d

J&J's ketamine-derived nasal spray approved by FDA to treat depression

Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those who had an inadequate response to oral antidepressants.

CNN on MSN · 2d

FDA approves standalone use of J&J’s ketamine-derived depression treatment

The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used as a standalone treatment for patients with severe depression, the company said on Tuesday.

ScienceAlert on MSN12h

FDA-Approved Nasal Spray For Depression Is First Of Its Kind

A ketamine-based nasal spray is officially the first and only standalone therapy available for treatment-resistant depression in the US.

BioSpace17h

J&J Says Deals Likely to Shrink After $14.6B Intra-Cellular Buy

On the company’s Q4 earnings call where an eyepopping $88.8 billion in full-year sales were revealed, leaders shifted focus ...

21h

Pregnancy raises risks to mental health in MS patients, study says

Overall, women with MS have a 26% increased risk of mental illness during pregnancy and a 33% increased risk after giving birth, compared to women without the degenerative nerve disease.

Johnson & Johnson: Hold Rating Amid Mixed Performance and Future Uncertainties

Analyst Tim Anderson of Bank of America Securities reiterated a Hold rating on Johnson & Johnson (JNJ – Research Report), reducing the ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results